TY - JOUR
KW - CNS
KW - MEA
KW - NAMs
KW - Drug development
KW - Drug Discovery
KW - drug safety
KW - epilepsy
KW - hiPSC neurons
KW - ion channels
KW - seizure
AU - Ruth A. Roberts
AU - Mamta Behl
AU - Helena T. Hogberg
AU - Eduardo Dunayevich
AU - Michael Morton
AU - Kimberly L. Rockley
AU - Abigail L. Walker
AU - Jennifer B. Pierson
AB - Seizures are the hallmark of treatment-resistant epilepsy and are also a frequent adverse event in drug safety testing. Here we present a critical evaluation of new approach methodologies (NAMs) in epilepsy research and seizure liability. Specifically, recent data have shown that seizure can be profiled using an in vitro seizure liability assay (iSLA) comprising a microelectrode array (MEA) of human induced pluripotent stem cell (iPSC) neurons coupled with a human ion channel panel. Adverse outcome pathways (AOPs) also offer a powerful NAM framework to map how key events can lead to an adverse outcome such as seizure. These NAMs offers an innovative approach to antiseizure medication research as well as to seizure risk testing in drug discovery and development.
BT - Drug Discovery Today
DA - 2025-12-03
DO - 10.1016/j.drudis.2025.104569
IS - 1
LA - eng
N2 - Seizures are the hallmark of treatment-resistant epilepsy and are also a frequent adverse event in drug safety testing. Here we present a critical evaluation of new approach methodologies (NAMs) in epilepsy research and seizure liability. Specifically, recent data have shown that seizure can be profiled using an in vitro seizure liability assay (iSLA) comprising a microelectrode array (MEA) of human induced pluripotent stem cell (iPSC) neurons coupled with a human ion channel panel. Adverse outcome pathways (AOPs) also offer a powerful NAM framework to map how key events can lead to an adverse outcome such as seizure. These NAMs offers an innovative approach to antiseizure medication research as well as to seizure risk testing in drug discovery and development.
PY - 2025
EP - 104569
T2 - Drug Discovery Today
TI - Use of new approach methodologies (NAMs) in epilepsy research and seizure risk assessment
VL - 31
SN - 1878-5832
ER -